Baird lowered the firm’s price target on Cencora to $283 from $287 and keeps an Outperform rating on the shares. The firm updated its guidance raising full-year 2024 earnings guidance for the fifth time. Off a higher FY24 base, FY25 initial outlook is expected at low end of LRP targets due to COVID-related comps and potential loss of FCS to be acquired in June 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR:
- Cencora Announces EPS Forecast and Evernorth Contract Renewal
- TD Cowen sees ‘minimal’ impact to Cencora FY25 EPS from Cigna change
- Cencora Enhances Governance and Executive Compensation Structures
- Cencora Expands Board, Announces New Member Appointments
- Walgreens sells shares of Cencora for roughly $1.1B of proceeds